{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 39,
  "pageCount": 415,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The slide uses a red box to highlight a specific time period in the C602-RWP study to question the validity of the efficacy results.",
  "elementsJson": [
    "paragraph",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/39",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-39",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We note that the basis of efficacy and FDA approval is nothing more than a sharp and rather fortuitous separation in HQ-CT scores in placebo arm (n=39) vs. DCCR (n=38) in the last 4 weeks of the 16-week withdrawal period (+4.5 pbo, +0.4 DCCR).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acad-39fad5c51864",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "chart",
      "text": "HQ-CT Total Scores Over Time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45550623-23a6-470b-aa48-6926d47a8bb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "HQ-CT Total Score",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acad-3fcb73b4ab2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Like the phase 3, the withdrawal study lacks credibility and was plagued with numerous discrepancies and problems, detailed in a separate chapter. We note that the basis of efficacy and FDA approval is nothing more than a sharp and rather fortuitous separation in HQ-CT scores in placebo arm (n=39) vs. DCCR (n=38) in the last 4 weeks of the 16-week withdrawal period (+4.5 pbo, +0.4 DCCR). If you’re astute, you’re also notice the time warp in the 4 different scales across the studies below....",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a149668-008c-43fd-8da6-f1ac6bc2a06e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://investors.soleno.life/static-files/48405466-3bcb-41d8-ae9e-76f388652c12",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce353cfd-fc64-4f54-8cfb-bb9b879fd1b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.32
      },
      "kind": "title",
      "text": "DCCR clinical studies – Soleno investor presentation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fa02bda-a274-406c-aac2-38d0240f14b3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "4f963ebb-e375-4fb6-bb5f-273cc7e76a94",
      "evidence": "The slide explicitly claims the study 'lacks credibility' and points to 'discrepancies' to undermine the company's efficacy claims.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}